Gilead Net Tangible Assets vs Retained Earnings Analysis
GILD Stock | USD 93.89 0.49 0.52% |
Gilead Sciences financial indicator trend analysis is much more than just examining Gilead Sciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gilead Sciences is a good investment. Please check the relationship between Gilead Sciences Net Tangible Assets and its Retained Earnings accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
Net Tangible Assets vs Retained Earnings
Net Tangible Assets vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gilead Sciences Net Tangible Assets account and Retained Earnings. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Gilead Sciences' Net Tangible Assets and Retained Earnings is -0.22. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Gilead Sciences, assuming nothing else is changed. The correlation between historical values of Gilead Sciences' Net Tangible Assets and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Gilead Sciences are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Net Tangible Assets i.e., Gilead Sciences' Net Tangible Assets and Retained Earnings go up and down completely randomly.
Correlation Coefficient | -0.22 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Gilead Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.30, whereas Issuance Of Capital Stock is forecasted to decline to about 295.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 27.3B | 27.3B | 27.1B | 28.5B | Interest Expense | 1.0B | 935M | 944M | 534.5M |
Gilead Sciences fundamental ratios Correlations
Click cells to compare fundamentals
Gilead Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gilead Sciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Short Long Term Debt Total | 24.6B | 31.4B | 26.7B | 25.2B | 25.0B | 26.2B | |
Other Current Liab | 6.5B | 7.2B | 8.9B | 7.1B | 7.7B | 8.1B | |
Total Current Liabilities | 9.8B | 11.4B | 11.6B | 11.2B | 11.3B | 11.8B | |
Total Stockholder Equity | 22.7B | 18.2B | 21.1B | 21.2B | 22.8B | 24.0B | |
Property Plant And Equipment Net | 4.5B | 5.0B | 5.1B | 5.5B | 5.3B | 5.6B | |
Net Debt | 13.0B | 25.4B | 21.4B | 19.8B | 18.9B | 19.8B | |
Retained Earnings | 19.4B | 14.4B | 16.3B | 15.7B | 16.3B | 17.1B | |
Accounts Payable | 713M | 844M | 705M | 905M | 550M | 518.2M | |
Cash | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.8B | |
Non Current Assets Total | 30.1B | 52.6B | 52.9B | 47.9B | 46.0B | 48.3B | |
Non Currrent Assets Other | 7.7B | 6.4B | 6.0B | 4.0B | 4.8B | 5.0B | |
Cash And Short Term Investments | 25.8B | 7.9B | 7.8B | 7.6B | 7.3B | 7.5B | |
Common Stock Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.5B | |
Liabilities And Stockholders Equity | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Non Current Liabilities Total | 29.2B | 38.8B | 35.3B | 30.7B | 28.1B | 29.5B | |
Other Current Assets | 1.4B | 2.0B | 2.1B | 1.8B | 2.4B | 1.3B | |
Other Stockholder Equity | 3.2B | 3.9B | 4.7B | 5.6B | 6.5B | 6.8B | |
Total Liab | 39.0B | 50.2B | 46.9B | 42.0B | 39.4B | 41.3B | |
Total Current Assets | 31.5B | 15.8B | 15.1B | 15.2B | 16.1B | 10.8B | |
Short Term Debt | 2.5B | 2.8B | 1.5B | 2.3B | 1.8B | 1.9B | |
Net Receivables | 3.6B | 4.9B | 4.5B | 4.8B | 4.7B | 2.4B | |
Property Plant And Equipment Gross | 4.5B | 5.0B | 7.0B | 7.7B | 7.8B | 8.2B | |
Accumulated Other Comprehensive Income | 85M | (60M) | 83M | 2M | 28M | 37.6M | |
Short Term Investments | 12.7B | 1.4B | 1.2B | 973M | 1.2B | 1.1B | |
Inventory | 2.1B | 3.0B | 2.7B | 2.8B | 1.8B | 1.3B | |
Other Liab | 6.5B | 9.5B | 35.3B | 7.3B | 8.4B | 8.8B | |
Other Assets | 3.1B | 4.8B | 6.0B | 1M | 1.2M | 1.1M | |
Long Term Debt | 22.1B | 28.6B | 25.2B | 23.0B | 23.2B | 12.2B | |
Property Plant Equipment | 4.5B | 5.0B | 5.1B | 5.5B | 6.3B | 6.6B | |
Net Tangible Assets | 4.6B | (23.0B) | (20.7B) | (16.0B) | (14.4B) | (13.7B) | |
Noncontrolling Interest In Consolidated Entity | 125M | 19M | (5M) | (31M) | (84M) | (79.8M) | |
Retained Earnings Total Equity | 19.4B | 14.4B | 16.3B | 15.7B | 18.0B | 12.7B | |
Long Term Debt Total | 22.1B | 28.6B | 25.2B | 23.0B | 26.4B | 19.7B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.42) | Dividend Share 3.06 | Earnings Share 0.09 | Revenue Per Share 22.703 | Quarterly Revenue Growth 0.07 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.